| Literature DB >> 33101314 |
Ludmila Lupu1, Annette Palmer1, Markus Huber-Lang1.
Abstract
Physical trauma can be considered an unrecognized "pandemic" because it can occur anywhere and affect anyone and represents a global burden. Following severe tissue trauma, patients frequently develop acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) despite modern surgical and intensive care concepts. The underlying complex pathophysiology of life-threatening ALI/ARDS has been intensively studied in experimental and clinical settings. However, currently, the coronavirus family has become the focus of ALI/ARDS research because it represents an emerging global public health threat. The clinical presentation of the infection is highly heterogeneous, varying from a lack of symptoms to multiple organ dysfunction and mortality. In a particular subset of patients, the primary infection progresses rapidly to ALI and ARDS. The pathophysiological mechanisms triggering and driving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced ALI/ARDS are still poorly understood. Although it is also generally unknown whether insights from trauma-induced ARDS may be readily translated to SARS-CoV-2-associated ARDS, it was still recommended to treat coronavirus-positive patients with ALI/ARDS with standard protocols for ALI/ARDS. However, this strategy was questioned by clinical scientists, because it was documented that some severely hypoxic SARS-CoV-2-infected patients exhibited a normal respiratory system compliance, a phenomenon rarely observed in ARDS patients with another underlying etiology. Therefore, coronavirus-induced ARDS was defined as a specific ARDS phenotype, which accordingly requires an adjusted therapeutic approach. These suggestions reflect previous attempts of classifying ARDS into different phenotypes that might overall facilitate ARDS diagnosis and treatment. Based on the clinical data from ARDS patients, two major phenotypes have been proposed: hyper- and hypo-inflammatory. Here, we provide a comparative review of the pathophysiological pathway of trauma-/hemorrhagic shock-induced ARDS and coronavirus-induced ARDS, with an emphasis on the crucial key points in the pathogenesis of both these ARDS forms. Therefore, the manifold available data on trauma-/hemorrhagic shock-induced ARDS may help to better understand coronavirus-induced ARDS.Entities:
Keywords: acute respiratory distress syndrome; lung; pathophysiology; severe acute respiratory syndrome coronavirus 2; trauma
Mesh:
Substances:
Year: 2020 PMID: 33101314 PMCID: PMC7546394 DOI: 10.3389/fimmu.2020.584514
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Similarities and differences of major changes of the innate immune response in clinical and experimental ARDS induced either by severe tissue trauma or SARS-CoV-2 viral infection.
| Target organ: lungs | ARDS | |
|---|---|---|
| Etiology | Trauma | Coronavirus |
| Trigger | DAMPs, PAMPs, hypoxia | PAMPs, DAMPs |
| Onset after insult, days | 2–5 ( | 6–12 ( |
| Mortality rate, % | 21.8 ( | 14.1 ( |
| Fluid phase immune response | ||
| - Complement | Complement activation ↑ ( | Complement activation ↑ ( |
| - Coagulation | Activation (thrombosis) ( | Activation, thrombosis ( |
| Cellular phase immune response | ||
| - Neutrophil | ↑↑ intrapulmonary recruitment and activation ( | ↑ intrapulmonary recruitment |
| - Macrophage | ↑ ( | ↑↑ ( |
| Air–blood barrier | ||
| - Lung epithelial cells | AT1 injury: sRAGE ↑ ( | AT2 entry for SARS-CoV-2 ( |
| - Lung endothelial cells | Endotheliopathy ↑ ( | Endotheliopathy ↑↑ ( |
DAMPs, danger-associated molecular patterns; PAMPs, pathogen-associated molecular patterns; DIC, disseminated intravascular coagulopathy; NETs, neutrophil extracellular traps; NLR, neutrophil/lymphocyte ratio; BGA, blood–gas analysis; AT1, alveolar type 1 cells; AT2, alveolar type 2 cells; Ang-2, angiopoietin 2; sRAGE, soluble receptor for advanced glycation end products.
Figure 1Alveolar immunopathophysiology during ARDS caused by severe tissue trauma (left side) or by SARS-CoV-2 infection (right side) with subsequent destruction, inflammation, thrombosis, and destruction. ARDS, acute respiratory distress syndrome; NETs, neutrophil extracellular traps; NLR, neutrophil/lymphocyte ratio; AT1, alveolar type 1 cells; AT2, alveolar type 2 cells; Ang-2, angiopoietin 2; sRAGE, soluble receptor for advanced glycation end products; SFP, surfactant protein; Hb, hemoglobin; BE, base excess; RBC, red blood cells (transfusion); ATIC, acute trauma-induced coagulopathy; Lymph, lymphocyte; C3, complement component 3; C3a, activated complement 3 (anaphylatoxin); C5a, activated complement 5 (anaphylatoxin); PEEP, positive end-expiratory pressure; paO2, partial arterial oxygen pressure; FiO2, fraction of inspired oxygen; GAGs, glycosaminoglycans; ICAM, intercellular adhesion molecule.